EmbarkNeuro is a neuroscience focused biotech company focused on bringing important new personalized treatments to patients with mental health disorders. Rates of major depression are rapidly rising, much of this attributable to the dramatic increase in stress brought on by the COVID-19 pandemic. We are focusing on identifying depressed individuals with a potential biomarker linked to the stress response system (elevated cortisol) and developing ANC-501 as a new treatment specifically for these patients. The time is right to think anew about how best to match patients to new treatments focusing on the underlying driver of symptoms.
In contrast to standard antidepressants, our technology is designed to address disruptions in the stress response system seen in many patients with depression, especially those with a history of Adverse Childhood Experiences (ACE’s) or other severe stressful or traumatic events.